Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 13/20 | 0.70 |
| ▸ | KMT2A | Q03164 | 13/20 | 0.70 |
| ▸ | POLB | P06746 | 8/20 | 0.70 |
| ▸ | CASP6 | P55212 | 4/20 | 0.70 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.70 |
| ▸ | TLR9 | Q9NR96 | 3/20 | 0.70 |
| ▸ | NPC1 | O15118 | 5/20 | 0.68 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.67 |
| ▸ | NPSR1 | Q6W5P4 | 5/20 | 0.64 |
| ▸ | MAPT | P10636 | 4/20 | 0.64 |
| ▸ | HTT | P42858 | 4/20 | 0.64 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.64 |
| ▸ | RAB9A | P51151 | 2/20 | 0.60 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.58 |
| ▸ | S1PR4 | O95977 | 2/20 | 0.55 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.55 |
| ▸ | HPGD | P15428 | 1/20 | 0.55 |
| ▸ | XBP1 | P17861 | 1/20 | 0.55 |
| ▸ | CCR6 | P51684 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6037133 | 0.92 | MEN1 (0.68) | MEN1KMT2APOLBCASP6L3MBTL1 | |
| SCHEMBL5157137 | 0.91 | MEN1 (0.64) | MEN1KMT2APOLBCASP6L3MBTL1 | |
| SCHEMBL4233357 | 0.88 | MEN1 (0.70) | MEN1KMT2APOLBCASP6L3MBTL1 | |
| SCHEMBL16213360 | 0.85 | KMT2A (0.68) | MEN1KMT2APOLBCASP6L3MBTL1 | |
| SCHEMBL8290567 | 0.83 | MEN1 (0.63) | MEN1KMT2APOLBCASP6L3MBTL1 | |
| SCHEMBL14510361 | 0.82 | MEN1 (0.77) | MEN1KMT2APOLBCASP6L3MBTL1 | |
| SCHEMBL4231252 | 0.82 | TYMS (0.65) | MEN1KMT2APOLBCASP6L3MBTL1 | |
| SCHEMBL14172750 | 0.81 | KMT2A (0.72) | MEN1KMT2APOLBCASP6L3MBTL1 | |
| SCHEMBL5168401 | 0.81 | KMT2A (0.73) | MEN1KMT2APOLBCASP6L3MBTL1 | |
| SCHEMBL19450676 | 0.80 | MEN1 (0.63) | MEN1KMT2APOLBCASP6L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7148352-B2 | Method of inhibiting neurotrophin-receptor binding | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 2006-12-12 | — | — | US | claimed |
| US-6468990-B1 | ADMINISTERING COMPOUNDS HAVING ELECTRONEGATIVE GROUPS WHICH INTERACT WITH CERTAIN LYSINE RESIDUES IN NERVE GROWTH FACTOR AND/OR HYDROPHOBIC MOIETY WHICH INTERACTS WITH HYDROPHOBIC REGION FORMED BY CERTAIN ISOLEUCINE AND PHENYLALANINE RESIDUES | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 2002-10-22 | — | — | US | claimed |
| US-20090215814-A1 | Method of inhibiting neurotrophin-receptor binding | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 2009-08-27 | — | — | US | disclosed |
| US-20070078137-A1 | Method of inhibiting neurotrophin-receptor binding | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 2007-04-05 | — | — | US | disclosed |
| US-7148352-B2 | Method of inhibiting neurotrophin-receptor binding | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 2006-12-12 | — | — | US | disclosed |
| US-20030186901-A1 | Method of inhibiting neurotrophin-receptor binding | MINE SAFETY APPLIANCES COMPANY | 2003-10-02 | — | — | US | disclosed |
| US-6468990-B1 | ADMINISTERING COMPOUNDS HAVING ELECTRONEGATIVE GROUPS WHICH INTERACT WITH CERTAIN LYSINE RESIDUES IN NERVE GROWTH FACTOR AND/OR HYDROPHOBIC MOIETY WHICH INTERACTS WITH HYDROPHOBIC REGION FORMED BY CERTAIN ISOLEUCINE AND PHENYLALANINE RESIDUES | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 2002-10-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090215814-A1 | Method of inhibiting neurotrophin-receptor binding | NGF, NTRK2, BDNF | MEN1 3489/4885KMT2A 3466/4885POLB 2851/4885 |
| US-20070078137-A1 | Method of inhibiting neurotrophin-receptor binding | NGF, NTRK2, BDNF | MEN1 3489/4885KMT2A 3466/4885POLB 2851/4885 |
| US-20030186901-A1 | Method of inhibiting neurotrophin-receptor binding | NGF, NTRK2, BDNF | MEN1 3799/4885KMT2A 3385/4885POLB 3115/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.